2026 Nobel Prize in Physiology or Medicine Announced, 12 Million Swedish Krona Shared by Three
The 2026 Nobel Prize in Physiology or Medicine was announced on October 5, awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their work on light-controlled ion channels and optogenetics. The prize of 12 million Swedish Krona will be shared among the three. Stanford subsequently released footage of Deisseroth in his campus lab.
Deisseroth, 54, is the D.H. Chen Professor in the Departments of Bioengineering and Psychiatry and Behavioral Sciences at Stanford, and a researcher at the Howard Hughes Medical Institute, holding both an M.D. and a Ph.D. in neuroscience. In the footage, he is seen walking through a corridor with a backpack, opening the lab door, without champagne or media crowds.
The award divides the discovery into two parts. Hegemann and Nagel found light-sensitive protein channels called channelrhodopsins in single-celled algae. Deisseroth developed these proteins into light switches for neurons: in 2005, he triggered neural signals in cultured rat neurons using blue light, and about two years later achieved this in the brains of live mice. The Karolinska Institute stated that light can turn on or off individual neurons in a living brain within milliseconds.
He established a training program at Stanford, distributing modified rhodopsin genes to laboratories worldwide, claiming to have trained thousands of users. As a psychiatrist, he emphasizes indirect applications: first identifying cells corresponding to symptoms, then designing drugs based on these circuits. Optogenetics has been adapted to restore limited light perception in a few blind individuals and is being tested for epilepsy, pain, and other conditions.
Stanford President Jonathan Levin stated that this work opens new possibilities for understanding the brain and treating neurological and psychiatric disorders. Deisseroth himself noted that the trio covers the entire path from algae exploration to neuroscience experimentation. Science pointed out that MIT's Edward Boyden, the first author of the key 2005 paper, who continued to advance the field, is not on the award list this time.
The buyers are laboratories that bring algal proteins into mammalian neural experiments, while the sellers are Stanford's research group providing genetic tools and training. The event was driven by the award announcement, not by new clinical approvals. Funding and attention will flow towards optogenetic circuit localization, then towards drugs and gene therapy trials designed based on these circuits. Beneficiaries are neuroscience laboratories that have mastered the tools, while traditional methods relying on broad electrical stimulation or resection to infer function are under pressure, along with parallel contributors not included in the award list.
The award was issued on October 5, with lab footage released afterward. The 12 million Krona is a share of honor, not an experimental budget.
Source: Public Information
ABAB AI Insight
The history of optogenetics began in German algal laboratories, not in clinical departments. Hegemann tracked how Chlamydomonas responded to light in half a millisecond since the early 1990s, and Nagel identified channelrhodopsin with him. Deisseroth's leap was to introduce microbial protein genes into rat neurons, then into mouse brains. The first author of the 2005 paper was Edward Boyden, who was still a Ph.D. student at the time; the award went to the corresponding author and the two protein discoverers, excluding Boyden. The Nobel Committee has repeatedly awarded tool prizes to three names while leaving parallel contributions in the papers.
The capital path moves from gene distribution to drugs. Stanford's research group distributes modified rhodopsins to laboratories worldwide, training thousands, effectively making the switch a public tool rather than a single patented clinic. Deisseroth repeatedly emphasizes indirect uses: using light to identify cells corresponding to depression, addiction, and epilepsy, then allowing pharmaceutical companies to design molecules based on these circuits. Directly inserting optical fibers into the human brain is not his emphasized endpoint. The restoration of limited light perception in a few blind individuals and trials for epilepsy and pain indicate that this path has already moved beyond mice.
A comparable case is the 2020 CRISPR Nobel Prize awarded to Doudna and Charpentier, where Feng Zhang's parallel patents and papers were not included. The industry position is that tools are now widespread, while treatments remain early: basic laboratories use light switches for causal experiments daily, but human adaptations are still limited to small-scale trials for vision, pain, and epilepsy. Psychiatric drugs were previously trialed based on symptom clusters; now there is a circuit map that can be illuminated before administering drugs.
This represents a technological replacement. The mechanism is that electrodes and drugs can only simultaneously affect a large group of cells, while light switches can target individual neurons and milliseconds. The award shifts pricing power from "who published behavioral experiments first" to "who turned algal proteins into usable switches." The unnamed first author illustrates that the distribution of scientific credit does not depend on the number of people at the experimental bench, but on the discovery chain selected by the committee. The image of a backpack entering the lab changes the visual but does not alter this credit accounting.
ABAB News · Cognitive Law
Once tools can be distributed, the award only remembers three names.
Those who illuminate circuits do not have to make drugs themselves.
The day after the honor is received, experiments are still behind the original door.